Acoustic Neuroma
14
2
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (14)
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Roy Adaptation Model Improves Mood and QOL After Giant Acoustic Neuroma
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Study of Aspirin in Patients With Vestibular Schwannoma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery
Auditory Nerve Test System During Vestibular Schwannoma Resection
Evaluating the Pre-Positioning Frame for Robotic Acoustic Neuroma Removal Surgery
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Acoustic Neuroma: Assessing the Quality of Life by the Scale PANQOL of Patients Operated or Supervised
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
RGD PET/MRI in Sporadic Vestibular Schwannoma